Search

Your search keyword '"Sands, Jacob"' showing total 228 results
Start Over Author "Sands, Jacob"
228 results on '"Sands, Jacob"'

2. Semiconductor-like Optical Properties Unveiled by Modeling of Short-Period Aluminum Oxide-Copper Multi-Layered Nanocomposites Deposited by Sputtering Atomic Layer Augmented Deposition (SALAD)

Author

Tornøe, Søren A., Sands, Jacob H., and Kobayashi, Nobuhiko P.

Subjects
Condensed Matter - Materials Science, Physics - Applied Physics, Physics - Optics
Abstract

In our previous publication, we discussed the optical properties of multi-layered nanocomposite samples consisting of 300 pairs of an AlOx layer and a Cu layer produced from sputtering atomic layer augmented deposition (SALAD). These samples displayed unusual spectral reflectance that could not be well described via conventional means and could not be explained as an interpolation of the constituent materials. Computational models were then needed to both describe the results that were obtained and to predict the samples' other material properties. This process was approached by using the transfer-matrix method to describe the spectral reflectance based on the constituent materials, and then the dispersion method was used to find the composite index of refraction for the samples. The models successfully described pure Cu but encountered minor difficulties when it came to AlOx, as such, more research is needed to either properly model non-holomorphic materials like AlOx with the current algorithm or to find a better model that can adequately describe both Cu and AlOx. The dispersion model implemented predicts that the samples, composed of many thin film layers of metal and dielectric, would display semiconductor-like behavior. Therefore, this indicates that SALAD's combination of sputtering and ALD permits the generation of novel metal-dielectric based semiconductors., Comment: 25 pages, 5 figures

Published
2022
Full Text
View/download PDF

5. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Author

Ganti, Apar Kishor P, Loo, Billy W, Bassetti, Michael, Blakely, Collin, Chiang, Anne, D'Amico, Thomas A, D'Avella, Christopher, Dowlati, Afshin, Downey, Robert J, Edelman, Martin, Florsheim, Charles, Gold, Kathryn A, Goldman, Jonathan W, Grecula, John C, Hann, Christine, Iams, Wade, Iyengar, Puneeth, Kelly, Karen, Khalil, Maya, Koczywas, Marianna, Merritt, Robert E, Mohindra, Nisha, Molina, Julian, Moran, Cesar, Pokharel, Saraswati, Puri, Sonam, Qin, Angel, Rusthoven, Chad, Sands, Jacob, Santana-Davila, Rafael, Shafique, Michael, Waqar, Saiama N, Gregory, Kristina M, and Hughes, Miranda

Subjects
Clinical Research, Cancer, Rare Diseases, Lung, Lung Cancer, Good Health and Well Being, Humans, Lung Neoplasms, Medical Oncology, Neoplasm Recurrence, Local, Small Cell Lung Carcinoma, Oncology & Carcinogenesis
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.

Published
2021

8. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Author

Argiris, Athanassios, Miao, Jieling, Cristea, Mihaela C, Chen, Allen M, Sands, Jacob M, Decker, Roy H, Gettinger, Scott N, Daly, Megan E, Faller, Bryan A, Albain, Kathy S, Yanagihara, Ronald H, Garland, Linda L, Byers, Lauren A, Wang, Ding, Koczywas, Marianna, Redman, Mary W, Kelly, Karen, and Gandara, David R

Subjects
Lung, Lung Cancer, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Rare Diseases, Orphan Drug, 6.1 Pharmaceuticals, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carboplatin, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Paclitaxel, Progression-Free Survival, Survival Rate, NSCLC, Thoracic radiotherapy, PARP inhibitors, carboplatin, paclitaxel, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundWe conducted a 2-part study to evaluate the incorporation of veliparib, a PARP inhibitor, into chemoradiotherapy (CRT) for stage III non-small-cell lung cancer.Patients and methodsIn the phase I part, patients were treated successively at 3 dose levels of veliparib (40, 80, and 120 mg) twice daily during CRT. In the phase II part, patients were randomized to receive veliparib or placebo during thoracic radiotherapy with concurrent weekly carboplatin and paclitaxel, followed by 2 cycles of consolidation carboplatin and paclitaxel with veliparib or placebo. The study was prematurely discontinued owing to the emergence of adjuvant immunotherapy as standard of care.ResultsOf 21 patients enrolled in phase I, 2 patients developed dose-limiting toxicities (DLTs): 1 grade 3 esophagitis with dysphagia (at 40 mg) and 1 grade 3 esophagitis with dehydration (at 80 mg). No DLTs were seen at veliparib dose of 120 mg twice daily, which was selected for the phase II part that enrolled 31 eligible patients. Progression-free survival (PFS) was not different between the 2 arms (P = .20). For the veliparib and placebo arms, response rates were 56% and 69%, PFS at 1 year 47% and 46%, and overall survival at 1 year 89% and 54%, respectively.ConclusionVeliparib with CRT was feasible and well tolerated. Efficacy could not accurately be determined because of early study closure. Nonetheless, there is enthusiasm for the evaluation of PARP inhibitors in lung cancer as predictive biomarkers are being developed and combinations with immunotherapy are attractive.

Published
2021

11. Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial.

Author

Aizer, Ayal, primary, Bi, Wenya Linda, additional, Catalano, Paul J., additional, Chipidza, Fallon, additional, Haas-Kogan, Daphne A., additional, Hertan, Lauren, additional, Kozono, David E., additional, Krishnan, Monica, additional, Mak, Raymond H., additional, Pashtan, Itai, additional, Peng, Luke, additional, Qian, Jack, additional, Rahman, Rifaquat, additional, Ricca, Ivy, additional, Sands, Jacob, additional, Shiloh, Ron Y., additional, Shin, Kee-Young, additional, and Tanguturi, Shyam Kumar, additional

Published
2024
Full Text
View/download PDF

12. Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.

Author

Owonikoko, Taofeek K., primary, Chiappori, Alberto, additional, Gentzler, Ryan D., additional, Liu, Stephen V., additional, Onitilo, Adedayo A., additional, Pennell, Nathan A., additional, Sands, Jacob, additional, Wang, Bo, additional, Lowenthal, Beth Hillary, additional, Bebchuk, Judith D., additional, Eli, Lisa DeFazio, additional, Wong, Elaine K., additional, and Dowlati, Afshin, additional

Published
2024
Full Text
View/download PDF

16. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.

Author

Shapira-Frommer, Ronnie, Niu, Jiaxin, Perets, Ruth, Peters, Solange, Shouse, Geoffrey, Lugowska, Iwona, Garassino, Marina C., Sands, Jacob, Keenan, Tanya, Zhao, Bin, Healy, Jane, and Ahn, Myung-Ju

Abstract

Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has shown promising antitumor activity, warranting further exploration of vibostolimab as a potential therapeutic option. The KEYVIBE program consists of nine trials that will evaluate the safety and efficacy of vibostolimab monotherapy and vibostolimab-based combination therapy in advanced solid tumors and hematological malignancies. These studies will also evaluate coformulated immunotherapy addressing issues that occur with the sequential administration of immunotherapy. The KEYVIBE program will provide further insight into the clinical utility of vibostolimab-based therapy across multiple indications and various stages of disease. Tweetable Abstract The KEYVIBE program consisting of nine trials will evaluate the safety and efficacy of the anti-TIGIT antibody vibostolimab across several tumor types. Trial registration: KEYVIBE-001 (NCT02964013); KEYVIBE-002 (NCT04725188); KEYVIBE-003 (NCT04738487); KEYVIBE-004 (NCT05005442); KEYVIBE-005 (NCT05007106); KEYVIBE-006 (NCT05298423); KEYVIBE-007 (NCT05226598); KEYVIBE-008 (NCT05224141); and KEYVIBE-010 (NCT05665595) (ClinicalTrials.gov). Executive summary Over the past decade, promising clinical efficacy has been observed with immune checkpoint inhibitors; however, there remains a subset of patients who do not respond or later develop resistance to treatment and experience tumor relapse. T-cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor that competitively inhibits the binding of the activating receptor CD226 with its ligands and is highly coexpressed with PD-L1. The binding of TIGIT to its ligands on tumor cells may contribute substantively to the suppression of T-cell signaling. Rationale for vibostolimab plus pembrolizumab combination therapy Vibostolimab is a novel humanized IgG1 monoclonal antibody that blocks TIGIT from interacting with its ligands and engages the Fc-γ receptor on myeloid cells. Vibostolimab and the PD-1 inhibitor pembrolizumab exert their effects through different pathways within the immune response cascade, making the combination an attractive option for further evaluation. KEYVIBE clinical trial program Early clinical data from the NSCLC cohort of the KEYVIBE-001 trial demonstrated promising antitumor activity and a favorable safety profile with sequentially administered vibostolimab plus pembrolizumab, leading to the development of the KEYVIBE program. The KEYVIBE program includes one phase I trial, three phase II trials, and five phase III trials investigating vibostolimab-based therapies in multiple solid tumor types and hematological malignancies and as various lines of therapy. Conclusion The wide selection of patients across the KEYVIBE trials will allow for a broad understanding of the patient populations that are most likely to benefit from vibostolimab and the treatment setting where vibostolimab is most likely to improve patient outcomes. The evaluation of coformulated vibostolimab-based therapy may also provide a solution to the drug administration challenges that arise with combination therapies that require sequential administration or different administration schedules. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

Author

Cañadas, Israel, Thummalapalli, Rohit, Kim, Jong Wook, Kitajima, Shunsuke, Jenkins, Russell William, Christensen, Camilla Laulund, Campisi, Marco, Kuang, Yanan, Zhang, Yanxi, Gjini, Evisa, Zhang, Gao, Tian, Tian, Sen, Debattama Rai, Miao, Diana, Imamura, Yu, Thai, Tran, Piel, Brandon, Terai, Hideki, Aref, Amir Reza, Hagan, Timothy, Koyama, Shohei, Watanabe, Masayuki, Baba, Hideo, Adeni, Anika Elise, Lydon, Christine Anne, Tamayo, Pablo, Wei, Zhi, Herlyn, Meenhard, Barbie, Thanh Uyen, Uppaluri, Ravindra, Sholl, Lynnette Marie, Sicinska, Ewa, Sands, Jacob, Rodig, Scott, Wong, Kwok Kin, Paweletz, Cloud Peter, Watanabe, Hideo, and Barbie, David Allen

Subjects
Genetics, Cancer, Vaccine Related, Immunization, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Animals, Cell Line, Tumor, Endogenous Retroviruses, Gene Expression Regulation, Neoplastic, Humans, Immunity, Innate, Interferons, Mice, Nude, Neoplasms, RNA, Antisense, Medical and Health Sciences, Immunology
Abstract

Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance1-4. This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies5-8, but remains incompletely defined. Here, we identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in these cells. Stimulated 3 prime antisense retroviral coding sequences (SPARCS) are oriented inversely in 3' untranslated regions of specific genes enriched for regulation by STAT1 and EZH2. Derepression of these loci results in double-stranded RNA generation following IFN-γ exposure due to bi-directional transcription from the STAT1-activated gene promoter and the 5' long terminal repeat of the antisense ERV. Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, sustaining a positive feedback loop. SPARCS induction in human tumors is tightly associated with major histocompatibility complex class 1 expression, mesenchymal markers, and downregulation of chromatin modifying enzymes, including EZH2. Analysis of cell lines with high inducible SPARCS expression reveals strong association with an AXL/MET-positive mesenchymal cell state. While SPARCS-high tumors are immune infiltrated, they also exhibit multiple features of an immune-suppressed microenviroment. Together, these data unveil a subclass of ERVs whose derepression triggers pathologic innate immune signaling in cancer, with important implications for cancer immunotherapy.

Published
2018

24. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Author

Trigo, José, Subbiah, Vivek, Besse, Benjamin, Moreno, Victor, López, Rafael, Sala, María Angeles, Peters, Solange, Ponce, Santiago, Fernández, Cristian, Alfaro, Vicente, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Zaman, Khalil, Boni, Valentina, Arrondeau, Jennifer, Martínez, Maite, Delord, Jean-Pierre, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Wannesson, Luciano, Valdivia, Javier, Rubio, María Jesús, Anton, Antonio, Sarantopoulos, John, Chawla, Sant P, Mosquera-Martinez, Joaquín, D'Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M, Sands, Jacob, and Paz-Ares, Luis

Published
2020
Full Text
View/download PDF

25. Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

Author

Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., and Awad, Mark M.

Published
2020
Full Text
View/download PDF

27. Sputtering Atomic Layer Augmented Deposition: A New Demonstration of Aluminum Oxide–Copper Dielectric–Metal Nanocomposite Thin Films

Author

Sands, Jacob

Subjects
Nanotechnology, Materials Science, Electrical engineering, Atomic Layer Deposition, Augmented, Nanocomposite, SALAD, Sputtering, Thin Films
Abstract

The specific machining process by which a thin film recipe is carried out determinesthe structure of each layer. For this reason, most precision thin films a recoatedusing techniques involving chemical species because of their consistent ability toform uniform structures. However, the set of chemicals that is able to form thinfilms is more limited than the set of its cousin’s technique of physically vaporizinga material source. Coupling this premise with the fact that it is advantageousto not expose a deposited sample to the atmosphere when transitioning from onedeposition method to another, we were inspired to combine atomic layer deposition(ALD) and magnetron sputtering (SPU) within a single chamber– sputteringatomic layer augmented deposition (SALAD). By hybridizing the two techniques,SALAD is capable of both ALD’s precise delivery and SPU’s diversity of materials.To demonstrate SALAD’s structural and optical capabilities, we madeseven different nanocomposites with 300 layers of aluminum oxide (AlOx) andcopper (Cu) thin films. After confirming that each AlOx-Cu nanocompositedeveloped distinct layers without cross-contamination, we were surprised to seethat the classical theory of effective medium approximation used to describe metal-dielectricoptical properties did not apply to the measured spectroscopicreflectivity data.

Published
2022

28. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Author

Ahn, Myung-Ju, primary, Cho, Byoung Chul, additional, Felip, Enriqueta, additional, Korantzis, Ippokratis, additional, Ohashi, Kadoaki, additional, Majem, Margarita, additional, Juan-Vidal, Oscar, additional, Handzhiev, Sabin, additional, Izumi, Hiroki, additional, Lee, Jong-Seok, additional, Dziadziuszko, Rafal, additional, Wolf, Jürgen, additional, Blackhall, Fiona, additional, Reck, Martin, additional, Bustamante Alvarez, Jean, additional, Hummel, Horst-Dieter, additional, Dingemans, Anne-Marie C., additional, Sands, Jacob, additional, Akamatsu, Hiroaki, additional, Owonikoko, Taofeek K., additional, Ramalingam, Suresh S., additional, Borghaei, Hossein, additional, Johnson, Melissa L., additional, Huang, Shuang, additional, Mukherjee, Sujoy, additional, Minocha, Mukul, additional, Jiang, Tony, additional, Martinez, Pablo, additional, Anderson, Erik S., additional, and Paz-Ares, Luis, additional

Published
2023
Full Text
View/download PDF

29. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Author

Levy, Benjamin P, primary, Felip, Enriqueta, additional, Reck, Martin, additional, Yang, James CH, additional, Cappuzzo, Federico, additional, Yoneshima, Yasuto, additional, Zhou, Caicun, additional, Rawat, Siddhartha, additional, Xie, Jingdong, additional, Basak, Priyanka, additional, Xu, Lu, additional, and Sands, Jacob, additional

Published
2023
Full Text
View/download PDF

33. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01.

Author

Shimizu, Toshio, Sands, Jacob, Yoh, Kiyotaka, Spira, Alexander, Garon, Edward B., Kitazono, Satoru, Johnson, Melissa L., Meric-Bernstam, Funda, Tolcher, Anthony W., Yamamoto, Noboru, Greenberg, Jon, Kawasaki, Yui, Zebger-Gong, Hong, Kobayashi, Fumiaki, Phillips, Penny, Lisberg, Aaron E., and Heist, Rebecca S.

Published
2023
Full Text
View/download PDF

34. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

Author

Huang, Richard S P, primary, Carbone, David P, additional, Li, Gerald, additional, Schrock, Alexa, additional, Graf, Ryon P, additional, Zhang, Liangliang, additional, Murugesan, Karthikeyan, additional, Ross, Jeffrey S, additional, Tolba, Khaled, additional, Sands, Jacob, additional, Oxnard, Geoffrey R, additional, and Spigel, David, additional

Published
2023
Full Text
View/download PDF

38. O13-6 Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study

Author

Shimizu, Toshio, primary, Kitazono, Satoru, additional, Garon, Edward B., additional, Johnson, Melissa L., additional, Lisberg, Aaron, additional, Spira, Alexander, additional, Yamamoto, Noboru, additional, Heist, Rebecca S., additional, Sands, Jacob M., additional, Meric-Bernstam, Funda, additional, Zenke, Yoshitaka, additional, Yanagitani, Noriko, additional, Greenberg, Jonathan, additional, Kobayashi, Fumiaki, additional, Kawasaki, Yui, additional, and Yoh, Kiyotaka, additional

Published
2022
Full Text
View/download PDF

39. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022

Author

Wood, Douglas E., primary, Kazerooni, Ella A., additional, Aberle, Denise, additional, Berman, Abigail, additional, Brown, Lisa M., additional, Eapen, Georgie A., additional, Ettinger, David S., additional, Ferguson, J. Scott, additional, Hou, Lifang, additional, Kadaria, Dipen, additional, Klippenstein, Donald, additional, Kumar, Rohit, additional, Lackner, Rudy P., additional, Leard, Lorriana E., additional, Lennes, Inga T., additional, Leung, Ann N.C., additional, Mazzone, Peter, additional, Merritt, Robert E., additional, Midthun, David E., additional, Onaitis, Mark, additional, Pipavath, Sudhakar, additional, Pratt, Christie, additional, Puri, Varun, additional, Raz, Dan, additional, Reddy, Chakravarthy, additional, Reid, Mary E., additional, Sandler, Kim L., additional, Sands, Jacob, additional, Schabath, Matthew B., additional, Studts, Jamie L., additional, Tanoue, Lynn, additional, Tong, Betty C., additional, Travis, William D., additional, Wei, Benjamin, additional, Westover, Kenneth, additional, Yang, Stephen C., additional, McCullough, Beth, additional, and Hughes, Miranda, additional

Published
2022
Full Text
View/download PDF

40. First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).

Author

Qin, Angel, primary, Kalemkerian, Gregory Peter, additional, Mohindra, Nisha Anjali, additional, Patel, Jyoti D., additional, Karapetis, Christos Stelios, additional, Carlisle, Jennifer W, additional, Sands, Jacob, additional, Spira, Alexander I., additional, Gao, Bo, additional, Amin, Harshad, additional, Paudyal, Bishnuhari, additional, Frank, Genevieve, additional, Sun, Xuemei, additional, Xu, Yang, additional, Wang, Cunlin, additional, Fu, Tommy, additional, Winkler, Robert, additional, Liang, Zhiyan, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2022
Full Text
View/download PDF

42. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

Author

Sands, Jacob, primary, Reck, Martin, additional, Navarro, Alejandro, additional, Chiang, Anne C., additional, Lu, Shun, additional, Peled, Nir, additional, Paz-Ares, Luis G., additional, Kerr, Samuel J., additional, Takahashi, Toshiaki, additional, Smolin, Alexey, additional, Chen, Xinqun, additional, Zhao, Bin, additional, El-Osta, Hazem Edmond, additional, and Califano, Raffaele, additional

Published
2022
Full Text
View/download PDF

43. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Author

Kehl, Kenneth L., primary, Zahrieh, David, additional, Yang, Ping, additional, Hillman, Shauna L., additional, Tan, Angelina D., additional, Sands, Jacob M., additional, Oxnard, Geoffrey R., additional, Gillaspie, Erin A., additional, Wigle, Dennis, additional, Malik, Shakun, additional, Stinchcombe, Thomas E., additional, Ramalingam, Suresh S., additional, Kelly, Karen, additional, Govindan, Ramaswamy, additional, Mandrekar, Sumithra J., additional, Osarogiagbon, Raymond U., additional, and Kozono, David, additional

Published
2022
Full Text
View/download PDF

50. O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Author

Shimizu, Toshio, primary, Lisberg, Aaron E., additional, Sands, Jacob M., additional, Greenberg, Jonathan, additional, Phillips, Penny, additional, Tajima, Naoyuki, additional, Kawasaki, Yui, additional, Gu, Jessie, additional, Kobayashi, Fumiaki, additional, Yamamoto, Noboru, additional, Johnson, Melissa, additional, Meric-Bernstam, Funda, additional, Yoh, Kiyotaka, additional, Garon, Edward B., additional, Heist, Rebecca S., additional, and Spira, Alexander, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results